vicriviroc
Small moleculeexperimental
Vicriviroc, previously named SCH 417690 and SCH-D, is a pyrimidine CCR5 entry inhibitor of HIV-1. It was developed by the pharmaceutical company Schering-Plough. Merck decided to not pursue regulatory approval for use in treatment-experienced patients because the drug did not meet primary efficacy endpoints in late stage trials. Clinical trials continue in patients previously untreated for HIV. — Wikipedia
Clinical trial activity
11 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
10
Phase 3
3
Phase 4
0
Earliest trial started May 1, 2004 (NCT00082498)
Timeline
Indications
Mechanism of action
- C-C chemokine receptor type 5ANTAGONIST
CCR5 antagonist
Discontinueddue to disappointing results in Ph2 and Ph3 studies.
Chemistry & pharmacology
Loading structure…
SMILES
COC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C- Mol. weight
- 533.64 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL82301 ↗
- WikipediaVicriviroc ↗
- ChEMBLCHEMBL2107384 ↗
Also known as
- 1-((4,6-dimethyl-5-pyrimidinyl)carbonyl)-4-(4-(2-methoxy-4-(trifluoromethyl)phenyl)ethyl-3-methyl-1-piperazinyl)-4-methylpiperidine
- 4-((4-bromophenyl)-(ethoxyimino)methyl)-1'-((2,4-dimethyl-3-pyridinyl)carbonyl)-4'-methyl-1,4'-bipiperidine n-oxide
- mk-4176
- mk-4176
- sch351125
- sch 351125
- sch-351125
- sch-351125
- sch-351125
- sch417690
- sch 417690
- sch-417690
- sch-417690
- sch-417690
- sch-c cpd
- schering c
- vicriviroc
- vicriviroc
- vicriviroc
- vicriviroc
- vicriviroc maleate
- vicriviroc maleate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03631407 | Phase 2 | Sep 27, 2018 | Merck |
| NCT00766597 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2009 | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), University of California, Berkeley, University of California, San Diego |
| NCT00632073 | Phase 1 | Mar 1, 2008 | Merck |
| NCT00551018 | Phase 2 | Dec 1, 2007 | Merck |
| NCT00551330 | Phase 2 | Sep 1, 2007 | Merck |
| NCT00523211 | Phase 3 | Jul 1, 2007 | Merck |
| NCT00474370 | Phase 3 | May 1, 2007 | Merck |
| NCT00243568 | Phase 3 | Sep 1, 2005 | Schering-Plough |
| NCT00243230 | Phase 2 | Sep 1, 2005 | Merck |
| NCT00686829 | Phase 2 | Jun 1, 2005 | Merck |
| NCT00082498 | Phase 2 | May 1, 2004 | AIDS Clinical Trials Group, Cornell University, Harvard University, Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 8 | 8 | 3 | 2005 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 2 | 1 | 2004 |
| AIDS Clinical Trials Group | Academic/Hospital | 1 | 0 | 1 | 2004 |
| Cornell University | Academic/Hospital | 1 | 0 | 1 | 2004 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2004 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2004 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2009 |
| Schering-Plough | For profit | 1 | 1 | 1 | 2005 |
| University of California, Berkeley | Academic/Hospital | 1 | 0 | 1 | 2009 |
| University of California, San Diego | Academic/Hospital | 1 | 0 | 1 | 2009 |
10 organizations
Page 1 / 1